A novel experimental drug for early Parkinson's disease (PD) yielded similar results as commercially available pramipexole extended-release (ER) but with significantly less daytime sleepiness, a new ...
Patients with Parkinson disease demonstrated significant reduction in depressive symptoms with citalopram and pramipexole, with pramipexole showing slightly more benefit in improving quality of life.
The fixed-dose combination therapy was found to be superior to each component. A phase 3 study evaluating a novel fixed-dose combination of extended release (ER) formulations of pramipexole and ...
Pramipexole dihydrochloride extended-release 0.375mg, 0.75mg, 1.5mg, 2.25mg, 3mg, 3.75mg, 4.5mg; tabs. Swallow whole. May take with food. Initially 0.375mg once daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback